Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Jansz TT, Young KG, Hopkins R, et al.
Diabetologia. Pub. online 9 Nov 2025.
Leggi
Breaking news
Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab
Mathieu C, Sims EK, Chatenoud L, et al.
Diabetes Care. Pub. online 6 Nov 2025.
Leggi
Hemoglobin A1c time-in-range, mortality, and diabetes complications in older adults with diabetes
Conlin PR, Prentice JC, Mohr DC, et al.
BMJ Open Diabetes Res Care. Pub. online 4 Nov 2025.
Leggi
Lantidra (donislecel) in type 1 diabetes: an in-depth analysis of pharmacology, clinical effectiveness, safety, and the therapeutic role of the first FDA-approved allogeneic islet cell therapy
Erbasan E, Aliciaslan M, Erendor F, et al.
Diabet Med. Pub. online 11 Nov 2025.
Leggi
Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: a population-based cohort study in England
Astbury NM, Ripullone K, Ramakrishnan R, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2025.
Leggi
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: a population-based cohort study in England
Astbury NM, Ripullone K, Ramakrishnan R, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2025.
Leggi
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
le Roux CW, Wharton S, Bozkurt B, et al.
Diabetes Obes Metab. Pub. online 4 Nov 2025.
Leggi
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi